Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 19.05.2025 3 Ann Oncol 1 Ann Surg Oncol 1 Ann Thorac Surg 3 BMC Cancer 1 Br J Cancer 2 Cancer 2 Cancer Cell 3 Cancer Lett 3 Cancer Res 1 Carcinogenesis 6 Chest 4 Clin Lung Cancer 1 Int J Oncol 1 J Cancer Res Clin Oncol 1 J Clin Invest 8 J Thorac Oncol 11 Lung Cancer 2 Oncogene 1 Oncol Rep 2 Oncologist 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. ROCCO G
   Letter to the Editor: Comments on the study of lung cancer detection by electronic nose analysis of exhaled breath.
   Ann Oncol. 2025 May 12:S0923-7534(25)00196-6. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   
2. SZARPAK L, Pruc M, Bizon M, Olszewski M, et al
   Validation Study of Electronic Nose Detection for Lung Cancer.
   Ann Oncol. 2025 May 12:S0923-7534(25)00197-8. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   
3. LIU J, Shi Y, Yang Y
   Letter Re: Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study.
   Ann Oncol. 2025 May 12:S0923-7534(25)00195-4. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   

   
   Ann Surg Oncol

4. SU XE, Lin CL, Wang HG, Jing-Liu, et al
   Development and Validation of a Machine Learning-Based Predictive Model for Postoperative Frailty in Patients with Non-Small Cell Lung Cancer and Its Relation to Early Recovery.
   Ann Surg Oncol. 2025 May 14. doi: 10.1245/s10434-025-17353.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

5. KALTMAN M, Yalamanchili S, Park JA, Weyant MJ, et al
   High catchment areas for lung cancer screening-eligible patients.
   Ann Thorac Surg. 2025 May 13:S0003-4975(25)00414.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. CHEN X, Wang K, Liao Y, Zheng C, et al
   Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis.
   BMC Cancer. 2025;25:862.
   PubMed         Abstract available
   
   
7. YAO J, Geng Y, Xu J, Zou B, et al
   The impact of EGFR mutation and PD-L1 status on the efficacy of postoperative radiotherapy in stage III-pN2 NSCLC.
   BMC Cancer. 2025;25:858.
   PubMed         Abstract available
   
   
8. ZHENG C, Miao J, Xu L, Cai Y, et al
   Novel PET imaging biomarkers as predictors of postoperative recurrence in lung adenocarcinoma.
   BMC Cancer. 2025;25:874.
   PubMed         Abstract available
   
   

   
   Br J Cancer

9. THOMAS C, Heathcote L, Sun Y, Callister MEJ, et al
   Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England.
   Br J Cancer. 2025 May 14. doi: 10.1038/s41416-025-03043.
   PubMed         Abstract available
   
   

   
   Cancer

10. HOFF CO, Feng L, Bonini F, Sousa LG, et al
    Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma.
    Cancer. 2025;131:e35901.
    PubMed         Abstract available
    
    
11. SHOU J, Chen J, Guo Q, Hong W, et al
    Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial.
    Cancer. 2025;131:e35822.
    PubMed         Abstract available
    
    

    
    Cancer Cell

12. TENG M, Guo J, Xu X, Ci X, et al
    Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.
    Cancer Cell. 2025;43:891-904.
    PubMed         Abstract available
    
    
13. LI Y, Oser MG
    A circular RNA in neuroendocrine carcinomas.
    Cancer Cell. 2025;43:812-814.
    PubMed         Abstract available
    
    

    
    Cancer Lett

14. WADE WEI TY, Hsia JY, Yang TY, Huang YX, et al
    Mechanistic Insights into CLNS1A-Mediated Chemoresistance and Tumor Progression in Non-small Cell Lung Cancer.
    Cancer Lett. 2025 May 7:217783. doi: 10.1016/j.canlet.2025.217783.
    PubMed         Abstract available
    
    
15. LUCA AC, Kurnaeva M, John DK, Machtinger M, et al
    Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma.
    Cancer Lett. 2025;623:217733.
    PubMed         Abstract available
    
    
16. JIANG M, Zhang K, Wei G, Qi F, et al
    HDAC4 super-enhancer drives CEBPB-mediated TWIST2 transcription to promote chemoresistance in LUAD.
    Cancer Lett. 2025;623:217716.
    PubMed         Abstract available
    
    

    
    Cancer Res

17. WANG K, Li J, Zhang H, Ma H, et al
    Tobacco Smoking Rewires Cell Metabolism by Inducing GAPDH Succinylation to Promote Lung Cancer Progression.
    Cancer Res. 2025 May 14. doi: 10.1158/0008-5472.CAN-24-3525.
    PubMed         Abstract available
    
    
18. QU T, Song L, Xu J, Lu X, et al
    MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer.
    Cancer Res. 2025 May 14. doi: 10.1158/0008-5472.CAN-23-3748.
    PubMed         Abstract available
    
    
19. TONG X, Lin G, Ji H
    "Dr. Jekyll and Mr. Hyde": AT2 Cells in Lung Regeneration and Tumor Development.
    Cancer Res. 2025;85:1753-1754.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

20. MA H, Wang G, Miao S, Jin C, et al
    Genetic susceptibility to lung squamous cell carcinoma: new insights on 9q33.2 variants and tobacco smoking.
    Carcinogenesis. 2025;46:bgaf018.
    PubMed         Abstract available
    
    

    
    Chest

21. BADE B, Faiz SA, Tan M, Baugh AD, et al
    The Impact of Healthcare Disparities on Lung Cancer Screening and Treatment.
    Chest. 2025 May 9:S0012-3692(25)00573-2. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    
22. JIANG J, Rao Y, Liu C, Chang SJ, et al
    A 7-Year-Old Girl With Multiple Pulmonary Nodules.
    Chest. 2025;167:e161-e165.
    PubMed         Abstract available
    
    
23. TOHMASI S, Eaton DB Jr, Rossetti NE, Heiden BT, et al
    Practice Patterns and Patient Travel Distances for Lung Cancer Surgery in the United States: Analyses of the Veterans Health Administration and the National Cancer Database.
    Chest. 2025 May 8:S0012-3692(25)00563-X. doi: 10.1016/j.chest.2025.
    PubMed        
    
    
24. EZENWANKWO E, Jones C, Nguyen DT, Eberth JM, et al
    Lung Cancer Screening Adherence in Centralized versus Decentralized Screening Programs A Meta-Analysis of U.S. Cohort Studies Among Individuals with Negative Baseline Results.
    Chest. 2025 May 7:S0012-3692(25)00559-8. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    
25. ABRAHAMS JM, Creekmur B, Lee JS, Amy Liu IL, et al
    Neighborhood-Level Socioeconomic Disadvantage and Adherence to Guidelines for the Evaluation of Patients With Incidentally Detected Pulmonary Nodules.
    Chest. 2025;167:1497-1508.
    PubMed         Abstract available
    
    
26. FENG Y, Kang H, Sood A, Guest DD, et al
    Dietary Pattern, Sputum DNA Methylation, and Lung Health: An Epidemiological Study in People Who Ever Smoked.
    Chest. 2025;167:1333-1345.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

27. OH MS, Garon EB, Lisberg AE, Cummings AL, et al
    Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients.
    Clin Lung Cancer. 2025 Mar 31:S1525-7304(25)00057.
    PubMed         Abstract available
    
    
28. LEE YG, Seo D, Gil HI, Lee H, et al
    Assessment of Lung Cancer Risks Related to Family History in Never-Smokers: A Cohort Study.
    Clin Lung Cancer. 2025 Apr 8:S1525-7304(25)00061.
    PubMed         Abstract available
    
    
29. TOPKAN E, Ozturk D, Selek U
    Comment on: Association of Sarcopenia with Toxicity and Survival in Patients With Lung Cancer, a Multi-Institutional Study With External Dataset Validation.
    Clin Lung Cancer. 2025 Apr 14:S1525-7304(25)00075.
    PubMed        
    
    
30. OHAEGBULAM K, Anderson C, Thompson RF, Mitin T, et al
    Common Medical Comorbidities Influence Pneumonitis Risk After Chemoradiotherapy and Durvalumab Maintenance in Stage III Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Apr 24:S1525-7304(25)00082.
    PubMed         Abstract available
    
    

    
    Int J Oncol

31. WANG SQ, Zhao BX, Liu Y, Wang YT, et al
    [Corrigendum] New application of an old drug: Antitumor activity and mechanisms of doxycycline in small cell lung cancer.
    Int J Oncol. 2025;66:48.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

32. WU KW, Deng SY, Zhang XF, Zheng DW, et al
    Thoracoscopy-guided thoracic paravertebral block using dexmedetomidine in combination with ropivacaine for postoperative analgesia after thoracoscopic radical resection of lung cancer: a randomized controlled trial.
    J Cancer Res Clin Oncol. 2025;151:158.
    PubMed         Abstract available
    
    

    
    J Clin Invest

33. APPADURAI MI, Chaudhary S, Shah A, Natarajan G, et al
    ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated immunosuppression and angiogenesis in non-small cell lung cancer.
    J Clin Invest. 2025;135:e186863.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

34. LINDBERG A, Muhl L, Yu H, Hellberg L, et al
    In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC.
    J Thorac Oncol. 2025;20:625-640.
    PubMed         Abstract available
    
    
35. YANAGISAWA A, Shiroyama T, Miyake K, Takeda Y, et al
    Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report.
    J Thorac Oncol. 2025;20:676-679.
    PubMed         Abstract available
    
    
36. WIESWEG M, Alaffas A, Rasokat A, Saalfeld FC, et al
    Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy.
    J Thorac Oncol. 2025 May 7:S1556-0864(25)00706.
    PubMed         Abstract available
    
    
37. DE-TORRES JP, Varo N
    The Tree That Let Us See the Forest: The Importance of Comorbidities in Lung Cancer Screening Programs.
    J Thorac Oncol. 2025;20:555-556.
    PubMed        
    
    
38. MREMI A, Ndumbalo J, Chuwa H, Henke O, et al
    Lung Cancer in Tanzania.
    J Thorac Oncol. 2025;20:560-564.
    PubMed        
    
    
39. WANG F, Bao M, Zhu L
    Refining Surgical Decision-Making for Elderly Patients With Lung Cancer: Recognized Risks, Unmet Needs.
    J Thorac Oncol. 2025;20:e62-e63.
    PubMed        
    
    
40. BOSTOCK I, Fox A, Engelhart K, Farjah F, et al
    Response to Letter to the Editor: "Refining Surgical Decision-Making for Elderly With Lung Cancer Patients: Recognized Risks, Unmet Needs".
    J Thorac Oncol. 2025;20:e63-e64.
    PubMed        
    
    
41. JONES SB, Chan C, Filippi AR, Harada K, et al
    Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommi
    J Thorac Oncol. 2025 May 9:S1556-0864(25)00710.
    PubMed         Abstract available
    
    

    
    Lung Cancer

42. FENG J, Hueniken K, Fan ZJ, Zhan LJ, et al
    Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations.
    Lung Cancer. 2025;204:108452.
    PubMed         Abstract available
    
    
43. LIN YD, Li HJ, Hong HZ, Qi YF, et al
    Genomic profiling of aggressive pathologic features in lung adenocarcinoma.
    Lung Cancer. 2025;203:108460.
    PubMed         Abstract available
    
    
44. BOSSE Y, Boudreau DK, Saavedra Armero V, Li Z, et al
    Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
    Lung Cancer. 2025;203:108530.
    PubMed         Abstract available
    
    
45. JIN W, Ding Z, Zhang M, Shen L, et al
    The global burden of mesothelioma and its association with asbestos bans, 1990-2021: a population-based study.
    Lung Cancer. 2025;203:108534.
    PubMed         Abstract available
    
    
46. NADAL E, Martin-Martorell P, Benitez JC, Sala MA, et al
    Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma.
    Lung Cancer. 2025;203:108545.
    PubMed         Abstract available
    
    
47. QIN Y, Mo Y, Li P, Liang X, et al
    Concurrent immunotherapy improves progression-free survival but increases toxicity in unresectable stage III NSCLC.
    Lung Cancer. 2025;203:108544.
    PubMed         Abstract available
    
    
48. WU K, Bi K, Shen M, Tang C, et al
    Decision-making tree model for distinguishing between benign and malignant subpleural pulmonary lesions based on ultrasonic strain elastography.
    Lung Cancer. 2025;203:108547.
    PubMed         Abstract available
    
    
49. CRESPI V, Delcuratolo MD, Minuti G, Montrone M, et al
    Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer.
    Lung Cancer. 2025;204:108576.
    PubMed         Abstract available
    
    
50. YANG G, Yoon HI, Lim SM, Hong MH, et al
    Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy.
    Lung Cancer. 2025;204:108574.
    PubMed         Abstract available
    
    
51. KAKIUCHI Y, Saruwatari K, Tokito T, Iriki T, et al
    Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.
    Lung Cancer. 2025;204:108578.
    PubMed         Abstract available
    
    
52. GOURLAY E, Banfill K, Merchant Z, Goodley P, et al
    Feasibility, acceptability and clinical outcomes of a real-world, regional lung cancer prehabilitation programme for patients undergoing curative intent radiotherapy.
    Lung Cancer. 2025;204:108572.
    PubMed         Abstract available
    
    

    
    Oncogene

53. LI S, Lin J, Huang L, Hu S, et al
    STK31 drives tumor immune evasion through STAT3-IL-6 mediated CD8(+) T cell exhaustion.
    Oncogene. 2025;44:1452-1462.
    PubMed         Abstract available
    
    
54. WANG C, Zhang S, Ma B, Fu Y, et al
    Correction: TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression.
    Oncogene. 2025 May 14. doi: 10.1038/s41388-025-03441.
    PubMed        
    
    

    
    Oncol Rep

55. YAN Y, Kong X, Jin X, Bu J, et al
    RNA?binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.
    Oncol Rep. 2025;54:74.
    PubMed         Abstract available
    
    

    
    Oncologist

56. XING P, Pu X, Zhou Y, Liu Z, et al
    Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC and brain metastasis: a multicenter cohort study.
    Oncologist. 2025;30:oyaf079.
    PubMed         Abstract available
    
    
57. HU X, Melson JW, Pan SS, Salei YV, et al
    Palliative and end-of-life care in Asian and White patients with metastatic lung cancer.
    Oncologist. 2025;30:oyaf065.
    PubMed         Abstract available
    
    

    
    PLoS One

58. LI Z, Zhu Z, Wang P, Hou C, et al
    Diagnostic, prognostic, and immunological roles of FUT8 in lung adenocarcinoma and lung squamous cell carcinoma.
    PLoS One. 2025;20:e0321756.
    PubMed         Abstract available
    
    
59. YIN X, Liang HW, Liu Y, Huang W, et al
    Lobectomy versus sublobar resection on survival in patients with stage T1-2N0M0 small cell lung cancer.
    PLoS One. 2025;20:e0324315.
    PubMed         Abstract available
    
    
60. 
    Retraction: Efficient lung cancer detection using computational intelligence and ensemble learning.
    PLoS One. 2025;20:e0324356.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.